Nalu

Nalu Medical, Inc. Presents Long-term and Holistic Outcomes from the COMFORT RCT for PNS at NANS 2024

Retrieved on: 
Tuesday, January 23, 2024
Neurology, Biotechnology, Physical Therapy, Surgery, Health, Medical Devices, Health Technology, Clinical Trials, North American Neuromodulation Society, Patient, PNS, Spinal cord, Research, Knee, NANS, RCT, Quality of life, Shoulder, Medicine, Pain, Spinal cord stimulator, SCS, Nerve, Chronic pain, Annual general meeting, Randomized controlled trial, Nalu, Physician, Pharmaceutical industry

The ongoing COMFORT RCT is a randomized, controlled, post-market, open-label, minimal risk, multi-center clinical study focused on evaluating the effectiveness of peripheral nerve stimulation (PNS) therapy with the Nalu Neurostimulation System to treat chronic pain in the shoulder, low back, knee, or ankle/foot.

Key Points: 
  • The ongoing COMFORT RCT is a randomized, controlled, post-market, open-label, minimal risk, multi-center clinical study focused on evaluating the effectiveness of peripheral nerve stimulation (PNS) therapy with the Nalu Neurostimulation System to treat chronic pain in the shoulder, low back, knee, or ankle/foot.
  • The study is designed to develop 3-year data to demonstrate the sustained pain relief and quality of life improvements achievable with the Nalu PNS system.
  • In the COMFORT RCT, we are measuring variables that present this broader picture.
  • “The COMFORT RCT is intended to provide reliable evidence of the sustained effectiveness and impact on quality of life provided by Nalu PNS therapy and to expand the use of Nalu PNS to patients for whom physicians have limited options.

Nalu Medical, Inc., Announces Positive Results of US Spinal Cord Stimulation Clinical Study in Pain Physician Journal

Retrieved on: 
Wednesday, November 29, 2023
Research, Surgery, Medical Devices, Neurology, Clinical Trials, Health Technology, Physical Therapy, Health, Science, Sleep, Brain, Pain management, Spinal cord, SCS, Patient, PNS, Nervous system, Medicine, FDA, IPG, Advantage Business Media, D Magazine, Trial of the century, Pain, Npower, R, Spinal cord stimulator, Nerve, Pain Physician, Physician, Quality of life, Dentistry, Medical imaging, Medical device, Nalu

Today the company announces publication of the SCS nPower™ US clinical study in the Pain Physician Journal that reports on clinical outcomes related to the use of the Nalu SCS System to treat patients suffering from chronic intractable pain of the of trunk and/or limbs, including unilateral or bilateral pain.

Key Points: 
  • Today the company announces publication of the SCS nPower™ US clinical study in the Pain Physician Journal that reports on clinical outcomes related to the use of the Nalu SCS System to treat patients suffering from chronic intractable pain of the of trunk and/or limbs, including unilateral or bilateral pain.
  • The SCS nPower US clinical study was a prospective, post-market observational study conducted at 15 comprehensive pain centers in the US.
  • The Nalu Neurostimulation System was evaluated in 35 subjects with chronic low back and leg pain from baseline to 3 months.
  • Highlights of the results include:
    The wearable Therapy Disc was reported by all patients to be comfortable and easy to use.

Nalu Medical, Inc. Ranked Number 19 Fastest Growing Company in North America in the 2023 Deloitte Technology Fast 500™

Retrieved on: 
Thursday, November 9, 2023
Technology, Medical Devices, Surgery, Seniors, Nanotechnology, Other Health, Biotechnology, Physical Therapy, Consumer, Health, Fintech, SCS, Neuropathic pain, Deloitte Technology Fast 500, Chronic pain, PNS, Medicine, Skin, Lithium, Telecommunications, Nalu, Patient, Pain, Pharmaceutical industry

Nalu Medical today announced that it ranked number 19 in the 2023 Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29th year.

Key Points: 
  • Nalu Medical today announced that it ranked number 19 in the 2023 Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29th year.
  • Within the life sciences category, the company ranked number 7.
  • Nalu chief executive officer, Tom West, credits the exceptional clinical performance and unique technology of the Nalu Neurostimulation System for the company’s 9,623% revenue growth rate.
  • A growing body of clinical data has clearly demonstrated the efficacy and lifestyle benefits for chronic pain patients of the Nalu System."

Kamaka Air Revitalizes Surfing Culture for Maui Survivors by Aiding in the Surfboard Replacement Project

Retrieved on: 
Monday, October 23, 2023
Surfboard, Life, Kapalua Airport, Kapalua, Hawaii, Atmosphere of Earth, Nalu, Partnership, Fire, Hospital

Kamaka Air’s partnership with Lau revitalizes Hawaii’s surfing culture for Maui survivors.

Key Points: 
  • Kamaka Air’s partnership with Lau revitalizes Hawaii’s surfing culture for Maui survivors.
  • So far, Kamaka Air has collected and transported over 80 donated surfboards to Maui.
  • “We are honored to continue our effort in restoring the Lahaina community in collaboration with Jud Lau and the Surfboard Replacement Project.
  • As Kamaka Air continues its philanthropic efforts in Maui, the Lahaina community further demonstrates its fortitude in reconstructing its livelihoods by riding on a wave of recovery and healing.

BDA’s Fifth Annual Bermuda Tech Summit To Be Held October 8-10

Retrieved on: 
Monday, August 14, 2023
Professional Services, Business, Thought Leadership, Other Professional Services, Finance, Consulting, Hub Culture, Panel, Partnership, Office of the Privacy Commissioner for Personal Data, One Communications, Data science, Scale Venture Partners, BMA, Insurance, Senior advisor, Buy, Silver, Privacy, Carbon, Hamilton Princess & Beach Club, Ministry, BDA, Demographics of Bermuda, Ministry of Economy (Spain), Gold, Economic development, Artificial intelligence, Continuity, Entrepreneurship, Blue economy, KPMG, Privacy Commissioner, Investment, Bermuda Monetary Authority, Sewage treatment, Cryptocurrency, Nalu, Fintech

The fifth annual Bermuda Tech Summit, presented by the Bermuda Business Development Agency (BDA), will be held from October 8-10, with the theme ‘Building a Foundation for the Future’.

Key Points: 
  • The fifth annual Bermuda Tech Summit, presented by the Bermuda Business Development Agency (BDA), will be held from October 8-10, with the theme ‘Building a Foundation for the Future’.
  • Additional topics will include climate tech, data privacy, carbon credit trading platforms, and pioneering digital assets.
  • The Bermuda Tech Summit, presented by the BDA is the signature event of the annual ‘Bermuda Tech Week’ being held from October 7-13 – stay tuned for more information about Bermuda Tech Week events in coming weeks.
  • An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions.

Nalu Medical, Inc. Presents Important New Clinical Data for PNS and SCS at ASPN 2023

Retrieved on: 
Thursday, July 20, 2023
Biotechnology, Health, Neurology, Clinical Trials, Human, Medicine, ODI, RCT, Spinal cord, Nalu, PNS, MCID, PGIC, Pain, Oswestry Disability Index, Patient, Physician, Engineering, Pain management, Spinal cord stimulator, ASPN, Society, Conference, PSP, SCS, Medical imaging, Neuroscience

The COMFORT RCT interim 6-month data show a 100% responder rate (≥50% reduction in pain) for subjects suffering from chronic peripheral neuralgia treated with the Nalu Peripheral Nerve Stimulation System (n=15).

Key Points: 
  • The COMFORT RCT interim 6-month data show a 100% responder rate (≥50% reduction in pain) for subjects suffering from chronic peripheral neuralgia treated with the Nalu Peripheral Nerve Stimulation System (n=15).
  • Additional highlights from the presentation include the following:
    78% mean pain relief from baseline.
  • The lead author, Dr. Mitchell Engle, noted, “Interim results show that the Nalu PNS System can provide sustained pain relief and functional improvement for patients with peripheral neuralgia.
  • This indicates that treatment with the Nalu SCS System provides a robust, holistic treatment response.” Nalu attributes results of this study to advanced engineering and the patented pulse stimulation pattern (PSP) waveform, which leverages multiple mechanisms of action in a single waveform3.

Nalu Medical, Inc. Announces First Enrollment of COMFORT-2 Peripheral Nerve Stimulation Randomized Controlled Trial

Retrieved on: 
Wednesday, May 31, 2023
Technology, Medical Devices, Surgery, Neurology, Clinical Trials, Nanotechnology, Biotechnology, Physical Therapy, General Health, Health, Ankle, Medicine, Diabetic neuropathy, Additive effect, Shoulder, SCS, American Society of Interventional Pain Physicians, Clinical trial, Trial of the century, Foot, Spinal cord, Nalu, Brain, PNS, Pain, Patient, Clinical study design, Randomized controlled trial, Neuropathic pain, Nerve, Pain management, Spinal cord stimulator, FDA, Chronic pain, Safety, Society, Treatment, Knee, Level 1, Medical device, Nursing, Medical imaging, Pharmaceutical industry, Neuroscience

Nalu Medical, Inc. (“Nalu”) a Carlsbad, California-based company that markets a minimally invasive neurostimulation implant for the management of chronic intractable pain for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications, announces the first patient enrollment in the Clinical Study Of A Micro-Implantable Pulse Generator For the Treatment of Peripheral Neuropathic Pain (COMFORT-2) Peripheral Nerve Stimulation Randomized Controlled Trial.

Key Points: 
  • Nalu Medical, Inc. (“Nalu”) a Carlsbad, California-based company that markets a minimally invasive neurostimulation implant for the management of chronic intractable pain for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications, announces the first patient enrollment in the Clinical Study Of A Micro-Implantable Pulse Generator For the Treatment of Peripheral Neuropathic Pain (COMFORT-2) Peripheral Nerve Stimulation Randomized Controlled Trial.
  • The Nalu PNS system incorporates a battery-free, micro implantable pulse generator (micro-IPG™), powered by an externally worn device (Therapy Disc) housing the battery and controller.
  • Dr. John Hatheway, interventional pain physician at Northwest Pain Care in Spokane, Washington, enrolled the first patient in the COMFORT-2 randomized controlled trial.
  • We are committed to being the leader in PNS clinical data development.”
    This is the second PNS randomized controlled trial sponsored by Nalu Medical.

Inogen Announces Appointment of Tom West to Board of Directors and Retirement of Board Member Kristen Miranda

Retrieved on: 
Wednesday, March 22, 2023
Biotechnology, Health Technology, Health, Medical Devices, Business development, Partnership, University, MBA, COVID, History, Princeton University, Economics, Wharton School of the University of Pennsylvania, Medtronic, Patient, Division, AdvaMed, Intersection, Johnson & Johnson, Family, Medtech, Worldwide, Management, Hologic, Nalu, Politics

The company also announced that Kristen Miranda, who has served as a director since March 2021, will retire as a member of the Board of Directors, effective March 31, 2023.

Key Points: 
  • The company also announced that Kristen Miranda, who has served as a director since March 2021, will retire as a member of the Board of Directors, effective March 31, 2023.
  • “We are pleased to welcome Tom West to the Inogen Board.
  • Mr. West served as an independent member of the Board of Directors of publicly traded Orthofix from 2021 to 2023.
  • “I am thrilled to have the opportunity to advance Inogen’s transformation into a global respiratory care leader,” said Tom West.

Runway Growth Finance Corp. Provides Fourth Quarter 2022 Portfolio Update

Retrieved on: 
Tuesday, January 10, 2023
Human, Air traffic control, Tenant, IO, Information services, Communication, IOT, Photography, Chronic pain, Madison Reed, Internet of things, Weight loss, Nalu, Vesta, Woman, Artificial intelligence, Growth, Health, Patient, Completion, TCON, EPIC, Investment, Obesity, Security (finance), Renewable energy, Health insurance, Video game, Airline, Bank

WOODSIDE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (“Runway Growth”) (Nasdaq: RWAY), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today provided an operational and portfolio update for the fourth quarter ended December 31, 2022.

Key Points: 
  • WOODSIDE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (“Runway Growth”) (Nasdaq: RWAY), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today provided an operational and portfolio update for the fourth quarter ended December 31, 2022.
  • “Runway Growth capitalized on its strong momentum in the venture lending space, completing twelve investments in new and existing portfolio companies, and delivering record fourth quarter and full year originations,” said David Spreng, Founder and CEO of Runway Growth.
  • In the fourth quarter of 2022, Runway Growth funded 12 investments: six investments in new portfolio companies, and six new investments in existing portfolio companies.
  • Runway Growth delivered its fourth consecutive quarter of record originations through deploying leverage and partnering with the highest quality late-stage companies to drive portfolio growth.

Open Book Extracts Partners with Nalu Bio to Commercialize Synthetic THCV and Rare Cannabinoids

Retrieved on: 
Wednesday, July 27, 2022
ISO, Aspirin, Chemistry, CBD, Cosmetics, Water, Capsule, Industry, Doctor of Philosophy, NSF, Pesticide, Tablet, THC, History, THCV, Research, Partnership, IP, Research Triangle, CBG, CBDV, Nature, CBT, CTO, Synthetic, Shikimate pathway, CBN, Nalu, Technology, Cannabinoid, Efficiency, OBX, CBC, Fine chemical

The partnership with OBX will allow Nalu Bio to advance its THCV production method from research and development to commercial-scale manufacturing using their proprietary and scalable synthesis platform.

Key Points: 
  • The partnership with OBX will allow Nalu Bio to advance its THCV production method from research and development to commercial-scale manufacturing using their proprietary and scalable synthesis platform.
  • THCV will be the first cannabinoid available at commercial scale through this partnership, allowing OBX and Nalu Bio to offer the highest quality, most consistent dosage of THCV to consumers across the globe.
  • Both OBX and Nalu Bio envision a range of additional cannabinoids to be released through this partnership.
  • The partnership with Nalu Bio will allow OBX to provide the industry with the highest quality synthetic rare cannabinoids at the lowest cost.